| pubmed-article:10880016 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C0017387 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C0016030 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C1545588 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:10880016 | lifeskim:mentions | umls-concept:C2698977 | lld:lifeskim |
| pubmed-article:10880016 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:10880016 | pubmed:dateCreated | 2000-10-18 | lld:pubmed |
| pubmed-article:10880016 | pubmed:abstractText | BLK mouse fibroblasts (H-2b) were genetically engineered to express costimulatory B7.1 and interleukin-2 (BLK/IL2/B7.1). The BLK/IL2/B7.1 cells were then pulsed with an ovalbumin (OVA) epitope as a model antigen (Ag) (BLK/IL2/B7.1/OVA), and tested for the induction of OVA-specific cytotoxic T lymphocytes (CTLs) in C57BL/6 mice (H-2b). The genetically engineered fibroblasts lacking one or two of three factors (interleukin-2, B7.1, and OVA) were constructed and used as controls. Immunization with the BLK/IL2/B7.1/OVA cells induced strong cytotoxic activities against OVA-expressing EL4 (EG7) tumor cells, but not against other H-2b tumor cells, such as EL4, C1498 and B16F1 cells. The magnitude of the cytotoxic response in mice with the BLK/IL2/B7.1/OVA cells was significantly higher than the response in mice immunized with any other cell constructs. CD8+ T cells with OVA-specific cytotoxic activities were predominant in mice immunized with the BLK/IL2/B7.1/OVA cells. Furthermore, immunization with the BLK/IL2/B7.1/OVA cells significantly prolonged the survival of mice, compared with any other cell constructs, when the mice were challenged with EG7 tumor cells at 2 weeks postimmunization. Induction of antitumoral CTL immunity by the BLK/IL2/B7.1/OVA cells was independent of host Ag-presenting cells and of CD4+ T-cell and natural killer 1.1+ cell help. These results suggest that fibroblasts can be genetically modified to efficient Ag-presenting cells for the induction of an Ag-specific CTL response. | lld:pubmed |
| pubmed-article:10880016 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10880016 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880016 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10880016 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880016 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880016 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880016 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880016 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10880016 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:10880016 | pubmed:issn | 0929-1903 | lld:pubmed |
| pubmed-article:10880016 | pubmed:author | pubmed-author:LeeJ WJW | lld:pubmed |
| pubmed-article:10880016 | pubmed:author | pubmed-author:CHUK MKM | lld:pubmed |
| pubmed-article:10880016 | pubmed:author | pubmed-author:MOER ERE | lld:pubmed |
| pubmed-article:10880016 | pubmed:author | pubmed-author:HwangS YSY | lld:pubmed |
| pubmed-article:10880016 | pubmed:author | pubmed-author:ChengC WCW | lld:pubmed |
| pubmed-article:10880016 | pubmed:author | pubmed-author:KatzA GAG | lld:pubmed |
| pubmed-article:10880016 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10880016 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:10880016 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10880016 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10880016 | pubmed:pagination | 861-9 | lld:pubmed |
| pubmed-article:10880016 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:meshHeading | pubmed-meshheading:10880016... | lld:pubmed |
| pubmed-article:10880016 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10880016 | pubmed:articleTitle | Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo. | lld:pubmed |
| pubmed-article:10880016 | pubmed:affiliation | College of Pharmacy, Chonnam National University, Kwangju, Republic of Korea. taekim@chonnam.chonnam.ac.kr | lld:pubmed |
| pubmed-article:10880016 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10880016 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
